In the news
Vilya Expands Series A Financing to $71 Million to Advance Computational Drug Design and Develop a New Class of Medicines
MORE NEWS
2
4/25/2024
Vilya Announces New Publication in Science Validating Foundational Approach to Design of Novel Chemically Diverse Macrocycles
6
08/30/2022
Fierce Biotech: Arch builds bridge to new class of medicines, leading $50M investment in the AI-enabled Vilyas
7
08/29/2022
Vilya launches to design a new transformational class of medicines that precisely target disease biology
9
08/29/2022
UW Institute for Protein Design: Design of membrane-traversing peptides leads to new spinout
10
08/29/2022
David Baker’s lab and ARCH sprout Lord of the Rings-inspired macrocycle biotech
11
08/29/2022
Timmerman Report: Arch bets $50M on Vilya, Baker Lab Spinout to Make Targeted, Oral Peptide Drugs
12
